Harpoon Therapeutics gets FDA fast track status for HPN217 in RRMM
Harpoon Therapeutics has bagged fast track designation for HPN217 from the US Food and Drug Administration (FDA) for the treatment of certain patient population with ... Read More
Natco Pharma faces legal setback for Imbruvica generic in US
Natco Pharma Limited said that a US District Court has given a decision in favor of Pharmacyclics, a subsidiary of AbbVie, the brand owner of ... Read More
AbbVie’s ibrutinib, venetoclax combo succeeds in phase 3 GLOW study
AbbVie said that the phase 3 GLOW study in chronic lymphocytic leukemia (CLL) investigating the combination of IMBRUVICA (ibrutinib) plus VENCLEXTA/VENCLYXTO (venetoclax) (I+V) has met ... Read More
AbbVie reports positive results for RINVOQ in SELECT-CHOICE phase 3 trial
AbbVie said that RINVOQ (upadacitinib, 15 mg, once daily) has met the primary endpoint and key secondary endpoints in the SELECT-CHOICE phase 3 trial in ... Read More
AbbVie wraps up $63bn acquisition of Irish drugmaker Allergan
US biopharma company AbbVie has wrapped up its previously announced $63 billion acquisition of Irish drugmaker Allergan following receipt of all the required approvals from ... Read More
AbbVie acquisition of Allergan gets antitrust clearance from US FTC
AbbVie acquisition of Allergan update : US biopharma company AbbVie has secured clearance from the US Federal Trade Commission (FTC) for its previously announced $63 ... Read More
Allergan to sell brazikumab to AstraZeneca and Zenpep to Nestle
Allergan has agreed to sell IL-23 inhibitor brazikumab to AstraZeneca and gastrointestinal medication Zenpep (pancrelipase) to Nestle in separate agreements, as per the latest pharma ... Read More
AbbVie, Scripps Research to collaborate on developing new therapeutics
US biopharma company AbbVie has entered into a collaboration with California-based nonprofit medical research facility Scripps Research with a goal to develop new therapies for ... Read More
Lupin collaborates with AbbVie for $977m MALT1 inhibitor program targeting hematological cancers
Indian pharmaceutical company Lupin has entered a landmark agreement to out-license its MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program to US-based biopharmaceutical ... Read More
Pfizer, AbbVie settle global IP for Humira biosimilar, paving way for European launch
In a significant step towards expanding biosimilar access, Pfizer and AbbVie have resolved all global intellectual property disputes concerning Pfizer’s proposed biosimilar to AbbVie’s blockbuster ... Read More